(S027) Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal Region

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.

Dana L. Casey, Leonard H. Wexler, MD, Michael P. LaQuaglia, MD, Paul A. Meyers, MD, Suzanne L. Wolden, MD, FACR; Memorial Sloan-Kettering Cancer Center

Purpose: Rhabdomyosarcoma of the perineal and perianal region (PRMS) has poor outcomes. We analyzed prognostic factors and patterns of failure, with an emphasis on radiotherapy for locoregional control.

Materials and Methods: Detailed records of all 15 patients treated for PRMS at Memorial Sloan-Kettering between 1998 and 2012 were reviewed. The Kaplan-Meier method was used to assess event-free survival (EFS) and overall survival (OS), and a competing-risks analysis was used to assess the cumulative incidence of local, regional, and distant failures.

Results: Median age was 15.1 years (range: 0.9–31.9 yr). High-risk features were identified: 73% of the patients had group III disease and 20% had group IV; 67% of tumors were alveolar; 87% of tumors were ≥ 5 cm; and 67% of patients had involved lymph nodes (N1). Of those aged ≥ 10 years at diagnosis, 89% had alveolar histology, 100% had tumors ≥ 5 cm, and 78% presented with N1 disease. The rates of local, regional, and distant failure at 5 years were 16%, 36%, and 35%, respectively. Although four of the five patients with regional failure received nodal irradiation, only one of the nodal failures occurred in the radiotherapy field. The 5-year EFS was 42%, and OS was 56%. Age ≥ 10 years was associated with poor outcomes: EFS was 15% in patients aged ≥ 10 years compared with 67% in those aged < 10 years (P = .04); the OS was 22% in patients aged ≥ 10 years compared with 100% in those aged < 10 years (P = .05).

Conclusions: Patients with PRMS, especially those aged ≥ 10 years, present with poor prognostic features and continue to have poor outcomes. Given the high incidence of regional node recurrence, we recommend prophylactic ilioinguinal lymph node irradiation for all patients aged ≥ 10 years. For children aged < 10 years, surgical evaluation of the ilioinguinal lymph nodes to determine the role for nodal irradiation is appropriate.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content